Pura Vida Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Pura Vida Investments’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,800	Closed	-$809K	–	176
2022 Q4	$809K	Sell	2,800 -23,963	-90%	-$7.3M	0.04%	150
2022 Q3	$7.75M	Buy	26,763 +10,000	+60%	+$2.88M	0.45%	60
2022 Q2	$4.72M	Sell	16,763 -67,294	-80%	-$18M	0.27%	93
2022 Q1	$21.9M	Buy	84,057 +59,421	+241%	+$14.1M	0.71%	32
2021 Q4	$5.41M	Sell	24,636 -5,364	-18%	-$1.04M	0.2%	108
2021 Q3	$5.44M	Buy	+30,000	New	+$5.86M	0.17%	142
2021 Q2	–	Sell	-10,243	Closed	-$2.2M	–	276
2021 Q1	$2.2M	Buy	+10,243	New	+$2.25M	0.06%	155
2018 Q3	–	Sell	-15,000	Closed	-$2.55M	–	130
2018 Q2	$2.55M	Buy	+15,000	New	+$2.33M	1.02%	35
2017 Q4	–	Sell	-29,900	Closed	-$4.55M	–	99
2017 Q3	$4.55M	Buy	+29,900	New	+$4.5M	1.33%	27

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pura Vida Investments's VRTX Position: Q1 2023 in Review

Pura Vida Investments sold out of Vertex Pharmaceuticals (VRTX) in Q1 2023, closing a stake of 2,800 shares — an estimated $809K sold.

Pura Vida Investments first reported a position in VRTX in Q3 2017 and held it in 9 quarters. The position peaked at $21.9M in Q1 2022. 1,208 funds tracked by Wall St. Rank hold VRTX as of Q1 2023.

Pura Vida Investments reported no remaining Vertex Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Pura Vida Investments sold 2,800 Vertex Pharmaceuticals shares in Q1 2023, an estimated $809K.
Pura Vida Investments first reported a position in Vertex Pharmaceuticals in Q3 2017 and held it in 9 quarters.
Pura Vida Investments's Vertex Pharmaceuticals position peaked at $21.9M in Q1 2022.
1,208 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.